One study including 24 HER2 exon 20 insertion lung cancer patients revealed that the overall survival of targeted therapy was longer than nontargeted agents, with 2.1 years and 1.4 years, respectively.18 Eng et al. reported 38 cases of HER2 mutated patients in which the PFS of HER2‐TKIs was 2.2 months, with 5.2 months for first‐line treatment and 1.8 months in later lines. The gene discussed is ERBB2; the disease is lung cancer.